PLEXIFORM NEUROFIBROMA
Clinical trials for PLEXIFORM NEUROFIBROMA explained in plain language.
Never miss a new study
Get alerted when new PLEXIFORM NEUROFIBROMA trials appear
Sign up with your email to follow new studies for PLEXIFORM NEUROFIBROMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for shrinking painful NF1 tumors
Disease control OngoingThis study tests a drug called mirdametinib in 114 adults and children with a genetic condition called NF1 that causes nerve tumors (plexiform neurofibromas) that cannot be surgically removed and cause serious problems. The goal is to see if the drug can shrink these tumors by at…
Matched conditions: PLEXIFORM NEUROFIBROMA
Phase: PHASE2 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated May 17, 2026 08:03 UTC
-
New hope for kids with Hard-to-Treat brain tumors: targeted drug shows promise
Disease control OngoingThis study tests an oral drug called trametinib in children and young adults (ages 1 month to 25 years) with low-grade glioma or plexiform neurofibroma that has not responded to other treatments. The drug targets a specific pathway (MAPK/ERK) that drives tumor growth. The main go…
Matched conditions: PLEXIFORM NEUROFIBROMA
Phase: PHASE2 • Sponsor: St. Justine's Hospital • Aim: Disease control
Last updated May 17, 2026 08:00 UTC
-
10-Year study aims to unlock mysteries of NF1
Knowledge-focused OngoingThis study follows 259 children and adults with Neurofibromatosis Type 1 (NF1) for up to 10 years to learn how the disease changes over time. Researchers use imaging, blood tests, and quality-of-life surveys to track tumors and other symptoms. The goal is to better understand NF1…
Matched conditions: PLEXIFORM NEUROFIBROMA
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 07, 2026 18:38 UTC